Enterprise Solutions Webinars

  1. Bioprocessing Equipment And Automation Product Portfolio Overview 5/19/2025

    Accelerate biotherapeutic development with innovative bioprocessing equipment and automation solutions that feature single-use mixers, bioreactors, and more to streamline workflows and speed products to market.

  2. The Next-Gen Cell Line Development Platform Fueling Biologics Success 5/19/2025

    Whether you're navigating the challenges of complex biologics or seeking a faster path to the clinic, this discussion sheds light on how innovation in CLD can be a game-changer for your pipeline.

  3. Do Novel Workflows Increase Regulatory Scrutiny? 5/16/2025

    David Bruehlmann, Ph.D. addresses continuous manufacturing in biopharma from the regulator’s perspective before sharing his view of where the technology is going next in this segment of the Bioprocess Online Live event Process Optimization or Full-Scale Automation. We discuss the chasm between the positive perception of continuous versus actual adoption, and discuss upcoming Bioprocess Online Live event programming.

  4. Does Continuous Complexity Outweigh Its Benefit? 5/16/2025

    In this segment of the Bioprocess Online Live event Process Optimization or Full-Scale Automation, David Bruehlmann, Ph.D. addresses how required tech investment, validation times, and staff training impact the return on continuous investment. We also analyze the results of an audience poll on process intensification adoption and discuss energy and perfusion media consumption in continuous versus batch processing.

  5. A Deeper Look At Product Quality Variables 5/16/2025

    David Bruehlmann, Ph.D. gives us a level-set on product quality variables in continuous versus batch biopharma manufacturing environments in this segment of the Bioprocess Online Live event Process Optimization or Full-Scale Automation. We also address audience questions on indication-specific hot spots for each approach, and whether continuous manufacturing is truly a “set it and forget it for weeks” proposition.

  6. Automation Adoption In Biopharma 5/16/2025

    This segment of the Bioprocess Online Live event Process Optimization or Full-Scale Automation features David Bruehlmann, Ph.D. and Johnson & Johnson Senior Director Irina Ramos, Ph.D. discussing the results of an audience poll on current levels of manufacturing automation in biopharma. We also cover audience questions on control strategies for impurity monitoring and the big question around whether volume is really the crux of the batch versus continuous debate.

  7. Product Quality, Process Complexity, And Cost Control 5/16/2025

    Johnson & Johnson Senior Director Irina Ramos, Ph.D. joins Bioprocessing expert David Bruehlmann for this segment of the Bioprocess Online Live event Process Optimization or Full-Scale Automation. The two discuss differences in product quality between fed batch and continuous, handling disruptions and quality control strategies, modality-specific considerations in continuous manufacturing, environmental and regulatory impacts, and more.

  8. Validation, PAT, And AI In Fed-Batch And Continuous Environments 5/16/2025

    During this segment of the Bioprocess Online Live event Process Optimization or Full-Scale Automation, David Bruehlmann, Ph.D. addresses audience questions on process analytical technology (PAT) validation, stressing the importance of process understanding before technology adoption. We also discuss AI’s value—and limitations—in current biopharmaceutical manufacturing environments.

  9. Facilities And Capital Considerations For Continuous Manufacturing 5/16/2025

    We entertained several audience questions during our recent Bioprocess Online Live event Process Optimization or Full-Scale Automation. In this segment from the virtual event, David Bruehlmann addresses questions about facility considerations for continuous manufacturing, highlighting findings from Amgen and that indicate continuous enabled a considerably smaller facility footprint than batch. Considerations for new facility investment decisions.

  10. Are You Team Batch Fed, Or Team Continuous? 5/16/2025

    In this segment of the Bioprocess Online Live event Process Optimization or Full-Scale Automation, we frame up the continuous vs. fed batch manufacturing debate, then jump right into the reliability and limitations of fed-batch environments. Bioprocessing expert David Bruehlmann, Ph.D. of The Smart Biotech Scientist Podcast fame also takes us on a deep, guided dive into the application of digital twins and real-time analytics in continuous operations.